SUPERNUS PHARMACEUTICALS, INC. Accounts Payable
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Accounts Payable of $5.59 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-03
- 2026-06-30: Accounts Payable, Current $5.59M.
- 2026-03-31: Accounts Payable, Current $10.17M.
- 2025-12-31: Accounts Payable, Current $2.68M.
- 2025-09-30: Accounts Payable, Current $8.18M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $5.59M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $10.17M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $2.68M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $8.18M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $8.21M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $7.07M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $4.59M 10-K · filed 2026-03-02 |
| 2024-09-30 | $6.39M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $4.63M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $14.40M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $1.96M 10-K · filed 2025-02-25 |
| 2023-09-30 | $3.39M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $4.40M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $11.54M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $10.54M 10-Q · filed 2023-11-08 |
| 2022-09-30 | $16.02M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $35.52M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $12.32M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $9.33M 10-K · filed 2023-03-09 |
| 2021-09-30 | $9.13M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $7.23M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $5.95M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $6.15M 10-K · filed 2022-04-13 |
| 2020-09-30 | $11.19M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $5.51M 10-Q · filed 2020-08-17 |
| 2020-03-31 | $3.12M 10-Q · filed 2020-05-15 |
| 2019-12-31 | $10.14M 10-K · filed 2021-03-08 |
| 2019-09-30 | $3.09M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $4.08M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $7.24M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $3.19M 10-K · filed 2020-02-28 |
| 2018-09-30 | $9.84M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $2.94M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $3.33M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $6.84M 10-K · filed 2019-03-01 |
| 2017-09-30 | $6.26M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $7.58M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $5.06M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $8.05M 10-K · filed 2018-03-01 |
| 2016-09-30 | $2.69M 10-Q · filed 2017-01-20 |
| 2016-06-30 | $2.24M 10-Q/A · filed 2017-01-23 |
| 2016-03-31 | $2.65M 10-Q/A · filed 2017-01-20 |
| 2015-12-31 | $4.31M 10-K · filed 2017-03-16 |
| 2015-09-30 | $2.81M 10-Q/A · filed 2017-01-20 |
| 2015-06-30 | $4.52M 10-Q/A · filed 2017-01-23 |
| 2015-03-31 | $859.00K 10-Q/A · filed 2017-01-20 |
| 2014-12-31 | $1.86M 10-Q/A · filed 2017-01-20 |
| 2014-09-30 | $1.57M 10-Q/A · filed 2017-01-20 |
| 2013-12-31 | $3.14M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |